CRVO — CervoMed Inc.

Nasdaq · Health Care · Pharmaceuticals · CIK 1053691 ·
Last close
$3.05
Market Cap
$28.24M
52W High
$5.12
52W Low
$2.82
ADV30
56,886
Next earnings
2026-08-13
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 0 -8,110,524 -7,964,158 15,112,918 7,941,751 4,497,203
Dec 2025 0 -8,331,519 -8,087,290 22,879,018 8,235,469 4,656,117
Sep 2025 0 -8,044,199 -7,726,639 30,610,778 9,437,400 4,599,314
Jun 2025 0 -6,616,275 -6,258,404 38,081,399 8,320,713 4,641,620

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-23,449,963
Investing CF
$18,097,249
Financing CF
$-13,340
CapEx
Dividends Paid
Buybacks
EPS Diluted TTM
$-2.79
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-97,697,851
Inventory
Receivables
$426,993
ST Investments
$12,628,970
EBIT TTM
$-28,294,877
Pretax Income TTM
$-26,966,367
Interest Exp TTM
Analysts
7

Yahoo Snapshot (yfinance, live)

Total Revenue
$2,089,019
EBITDA
Free Cash Flow
$-16,304,171
Enterprise Value
$15,407,699
Total Cash
$12,923,981
Total Debt
$0
Shares Out
9,258,719
Trailing EPS
$-3.29
Book Value
$1.15
ROE
-132.8%
ROA
-72.4%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 0 -28,294,877 -26,966,367 22,879,018 4,656,117 -23,449,963
Dec 2024 0 -18,227,131 -16,290,695 43,081,610 3,879,282 -16,530,827
Dec 2023 0 -7,812,895 -2,171,873 9,972,521 2,595,747 -7,449,847
Dec 2022 0 -3,475,534 -5,803,047 4,157,706 37,442,765 -2,572,759

TTM Snapshot

Revenues TTM
$12,839,780
NetIncome TTM
$-6,223,165
OpCashFlow TTM
$0
Assets (Latest)
$17,484,384
Forward EPS
$-2.39

Peers — same industry

TickerNameMarket CapLastDaily %
IGC IGC Pharma, Inc. $28.55M $0.29
GRDX GridAI Technologies Corp. $28.58M $4.61
BRNS Barinthus Biotherapeutics plc. $27.84M $0.68
KYNB KYNTRA BIO, INC. $27.73M $6.85
SER Serina Therapeutics, Inc. $28.80M $1.92

News headlines (Yahoo Finance, 1h cache)

CervoMed Reports First Quarter 2026 Financial Results and Provides Corporate Updates
2026-05-18 11:30 · Yahoo
Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates
2026-05-07 23:05 · Yahoo
IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue Estimates
2026-05-05 11:10 · Yahoo
CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies
2026-04-22 11:30 · Yahoo
CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting
2026-04-07 11:30 · Yahoo
CervoMed (CRVO)’s Q4 Results Feature Advancements in Its Neflamapimod Program for Dementia Lewy Bodies (DLB)
2026-03-25 19:28 · Yahoo
CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod’s Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer’s Disease Co-Pathol
2026-03-19 11:30 · Yahoo
CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
2026-03-17 11:30 · Yahoo
CervoMed Inc. (CRVO) Reports Q4 Loss, Lags Revenue Estimates
2026-03-13 22:15 · Yahoo
CervoMed Announces Presentations at Upcoming AD/PD™ 2026 Scientific Conference
2026-03-12 11:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.